Postdoctoral Researcher Omics & Multimodal Data Integration, R&D Neuroscience Data Science & Digital Health Full-time NEW

Postdoctoral Researcher Omics & Multimodal Data Integration, R&D Neuroscience Data Science & Digital Health

Our expertise in Innovative Medicine is informed and inspired by patients, whose insights fuel our science-based advancements. Visionaries like you work on teams that save lives by developing the medicines of tomorrow.

Join us in developing treatments, finding cures, and pioneering the path from lab to life while championing patients every step of the way.

Our Neuroscience Data Science & Digital Health team integrates the power of multi-omics, digital health technologies and clinical/real-world evidence (RWE) data to accelerate the delivery of transformational therapies for Neurodegeneration, Neuropsychiatry and Ophthalmology. We drive decision-making and breakthroughs from molecular discovery to clinical trials by partnering along the pipeline to ensure that data science and digital health strategies are embedded in every program.

We are seeking a Postdoctoral Researcher Omics & Multimodal Data Integration to join our team, with a specific focus on Alzheimer's disease.

This position can be located in either Beerse (Antwerp, Belgium), High Wycombe (United Kingdom), or Cambridge-MA/Spring House-PA (United States of America).

Please note that this role is available across multiple countries and may be posted under different requisition numbers to align with local requirements. While you are welcome to apply to any or all of the postings, we recommend focusing on the specific country(s) that align with your preferred location(s):

Belgium – Requisition Number: R-056279

Key Responsibilities:

• Develop and execute plans for the analysis & integration of multi-omics and other data modalities such as electronic health records and imaging data from Alzheimer's disease patient cohorts and human cell models, to develop patient stratification approaches for precision neuroscience, identify novel therapeutic targets, and enable the generation of innovative disease models in support of drug discovery.
• Partner closely with discovery and clinical scientists to ensure purposeful interrogation of multimodal human datasets and translation of data-derived hypotheses into clinical and wet lab validation plans.
• Build strong relationships with key internal and external partners to help shape academic collaborations and define the scope of the research questions.
• Remain current on the constantly evolving landscape of Alzheimer's disease and the use of omics, RWE data, and AI/ML in search of innovative approaches to derive biological insights that could accelerate and prioritize drug discovery.

Qualifications:

• PhD in neuroscience, computational biology, bioengineering, biostatistics, or a related field, completed within the past 3 years is required.
• Extensive hands-on expertise in analyzing and integrating multimodal omics data from patient cohorts and preclinical models is required.
• Proficiency in R, Python, or similar programming languages is required.
• Proven track record of scientific contributions in this field with first author publications is required.
• Ability to clearly communicate technical work to a diverse audience is required.
• Background and experience working in Neurodegeneration, and particularly Alzheimer's disease, is preferred.
• Experience analyzing other data modalities from observational studies such as electronic health record, digital health technology, imaging and biomarker data is preferred.
• Familiarity with machine learning and state-of-the-art AI methodologies is preferred.

This position currently has the option to follow a hybrid schedule of 3 days per week working on-site and 2 days per week working remotely (no fully remote option available) and can be located in one of our office locations in either Beerse (Antwerp, Belgium), High Wycombe (United Kingdom), Cambridge-MA/Spring House-PA (United States of America) or Zug (Switzerland).

The job may require approximately 10% travel domestic and international.